New drug shows promise for ulcerative colitis in early trial

NCT ID NCT03100864

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a drug called spesolimab in 8 adults with moderate to severe ulcerative colitis. The main goal was to understand how the drug works in the body, while also checking for safety and any signs of improvement. Participants received the drug for 12 weeks, and researchers looked at changes in genes from gut biopsies and markers of inflammation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Spesolimab (a drug given as an infusion)
What this could lead to: If successful, this could point toward a new treatment option for people with moderate to severe ulcerative colitis.
What could go wrong: This was a very small, early-phase trial with only 8 participants, so results may not apply to everyone. The main goal was to study how the drug works, not to prove it is effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLITIS, ULCERATIVE

Contacts and locations

Locations

Addenbrooke's Hospital

Cambridge, CB2 0QQ, United Kingdom
Asklepios Kliniken Westklinikum Hamburg

Hamburg, 22559, Germany
UZ Leuven

Leuven, 3000, Belgium
Universitätsklinikum Schleswig-Holstein, Campus Kiel

Kiel, 24105, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.